The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

The earnings season hasn't panned out well for pharma companies, with Amgen, Inc. (NASDAQ: AMGN), Novartis AG (NYS.....»»

The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves. read more.....»»

Biotech stocks held steady in the recent week as earnings from the sector continue to trickle in. The week also saw presentations of clinical t.....»»

The new year kick started with a bumper deal in the pharma space, with Bristol-Myers Squibb Co (NYSE: BMY) agreeing to buy Celgene Corporation (NASDAQ: read more.....»»

Biotech stocks pulled back in last week. Incidentally, some large-cap biotec.....»»

Biotech stocks pulled back in last week. Incidentally, some large-cap .....»»

Large-cap pharma stocks are seeing some upward momentum and are on track to f.....»»

Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be see.....»»

Biotech earnings news flow accelerated in last week, with Pfizer Inc. (NYSE: PFE) and Sanofi SA (NYSE: SNY) among the noteworthy releases of the week. With the earnin.....»»

Biotech earnings news flow accelerated in last week, with Pfizer Inc. (NYSE: PFE) and Sanofi SA (NYSE: SNY) among the noteworthy releases of the week. read more.....»»

As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. read more.....»»

After ending almost flat in the week ended Sept. 14, biotech stocks have seen some bounce in the running week, with the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) up about 1.3 percent through Thursday. read more.....»»

After ending almost flat in the week ended Sept. 14, biotech stocks have seen.....»»

After ending almost flat in the week ended Sept. 14, biotech stocks have seen some bounce in the running week, with the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) up about 1.3 percent through Thursday. read more.....»»

After ending almost flat in the week ended Sept. 14, .....»»

Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction to the release of clinical trial results. read more.....»»

After recording stellar gains of 4.3 percent in the week ended Aug. 31 to close the month in the green, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) saw a moderation in momentum in the holiday-shortened week ending Sept. 7. read more.....»»

After recording stellar gains of 4.3 percent in the week ended Aug. 31 to close the month .....»»

The biotech sector notched strong gains last week, capitalizing on the positive overall mark.....»»

The biotech .....»»